Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$17.1 - $22.26 $1.13 Million - $1.47 Million
66,244 New
66,244 $1.44 Million
Q2 2023

Aug 11, 2023

SELL
$40.65 - $59.54 $820,317 - $1.2 Million
-20,180 Reduced 54.43%
16,892 $794,000
Q1 2023

May 12, 2023

BUY
$37.27 - $46.57 $615,774 - $769,429
16,522 Added 80.4%
37,072 $1.56 Million
Q4 2022

Feb 10, 2023

BUY
$32.2 - $43.61 $221,697 - $300,254
6,885 Added 50.38%
20,550 $783,000
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $441,106 - $591,284
13,665 New
13,665 $535,000
Q2 2022

Aug 12, 2022

SELL
$27.52 - $37.99 $531,658 - $733,928
-19,319 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $161,381 - $240,206
-5,255 Reduced 21.38%
19,319 $639,000
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $28,610 - $36,368
-772 Reduced 3.05%
24,574 $1.05 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $1.02 Million - $1.45 Million
25,346 New
25,346 $1.12 Million
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $583,923 - $843,645
-10,640 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $211,102 - $289,118
2,988 Added 39.05%
10,640 $796,000
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $1.23 Million - $1.88 Million
-21,113 Reduced 73.4%
7,652 $661,000
Q3 2020

Nov 13, 2020

BUY
$41.13 - $62.45 $545,466 - $828,211
13,262 Added 85.54%
28,765 $1.76 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $402,302 - $668,954
15,503 New
15,503 $644,000
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $134,081 - $344,827
-2,228 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $136,361 - $184,641
-972 Reduced 30.38%
2,228 $312,000
Q2 2018

Aug 15, 2018

BUY
$140.36 - $175.76 $449,152 - $562,432
3,200 New
3,200 $500,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.